NUVECTIS PHARMA INC. news, videos and press releases
For more news please use our advanced search feature.
NUVECTIS PHARMA INC. - More news...
NUVECTIS PHARMA INC. - More news...
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
- Nuvectis Pharma to Participate in the 37th Annual Roth Conference
- Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
- Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
- Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
- Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights
- Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
- Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
- Nuvectis Pharma Announces Proposed Public Offering of Common Stock
- Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
- Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
- Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
- Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
- Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
- Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
- Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
- Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
- Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
- Nuvectis Pharma to Present at the 36th Annual Roth Conference
- Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
- Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
- Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
- Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
